

From: [Director_PTABDecision_Review](#)
To: ["Trask, Andrew"; Eylea; PGR46514-0017PS1](#)
Subject: RE: Alvotech v. Regeneron, PGR2025-00085
Date: Tuesday, March 24, 2026 6:57:00 AM

Counsel,

Patent Owner's request for an extension of the deadline to file a Request for Director Review in the above identified proceeding is denied. The Director's Memorandum applies to IPRs and PGRs in which the due date for a patent owner discretionary brief has not yet elapsed. See Memorandum, "Additional Discretionary Institution Considerations – U.S. Manufacturing and Small Business Use of AIA Proceedings," (March 11, 2026).

Thanks

PRG2025-00085
Ex. 3100

From: Trask, Andrew <atrask@wc.com>
Sent: Tuesday, March 17, 2026 7:27 PM
To: Director_PTABDecision_Review <Director_PTABDecision_Review@uspto.gov>
Cc: Eylea <Eylea@wc.com>; PGR46514-0017PS1 <PGR46514-0017PS1@fr.com>
Subject: Alvotech v. Regeneron, PGR2025-00085

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Honorable Director:

Patent Owner Regeneron Pharmaceuticals, Inc. writes to request an extension of the deadline to file a Request for Director Review of the March 3, 2026, decision granting institution in the proceeding of Alvotech v. Regeneron, PGR2025-00085. Regeneron is preparing a Director Review Request that addresses considerations set forth in the Director's March 11, 2026 Memorandum regarding additional institution considerations—namely, Regeneron's substantial American manufacturing and manufacturing investments in connection with the patent challenged in this proceeding. Regeneron submits that there is good cause for the extension in light of the Director's recently issued Memorandum. Regeneron respectfully requests an extension of 14 days, to March 31, 2026.

Regeneron sought the position of Petitioner Alvotech, which supplied the following statement:

Petitioner opposes Patent Owner's request for an extension of time because it is both untimely and unsupported by good cause. The Director instituted post-grant review in this case on March 3rd and the Director's Memorandum issued on March 11th. Despite having almost a full week, Patent Owner did not contact Petitioner until the afternoon of March 17th—the very day its Request for Director Review was due under 37 CFR 42.71(d)(1)—and then demanded a response within hours. Patent Owner's

lack of diligence in preparing a Request for Director Review during the intervening period does not constitute good cause. In addition, Patent Owner's request for an extension of time is unwarranted. The Memorandum expressly "applies to all IPRs and PGRs in which the due date for a patent owner discretionary brief has not yet elapsed." Here, the discretionary briefing period closed long ago, and Petitioner has already devoted resources to trial. Petitioner respectfully requests that Patent Owner's belated request for an extension of time be denied.

Respectfully submitted,

Andrew Trask

Counsel for Patent Owner Regeneron Pharmaceuticals, Inc.

Andrew Trask | Williams & Connolly LLP | 202-434-5023 | atrask@wc.com

This message and any attachments are intended only for the addressee and may contain information that is privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank you.